---
title: "Lysergide (DT120) in Generalized anxiety disorder: Other antidepressants"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Other antidepressants. Topics: CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone; BAP guideline: tricyclic antidepressants, agomelatine, and mirtazapine; Network meta-analysis: mirtazapine and agomelatine; Imipramine and trazodone compared with diazepam. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/other-antidepressants"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Other antidepressants

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Other Antidepressants

<a id="topic-2.2.2.1.9-1"></a>

### CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone

> “Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1)”
> “In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1)”
> “However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option.”
> “While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option”
> “Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive”
> “In a RCT, trazodone was as effective as diazepam (Level 2)”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.9-2"></a>

### BAP guideline: tricyclic antidepressants, agomelatine, and mirtazapine

> “TCAs are associated with a greater burden of adverse effects than either SSRIs or SNRIs”
> “TCAs should be avoided in patients considered to be at risk of suicide, due to their potential fatal toxicity after overdose”
> “elevations of hepatic enzymes occur in more than 1% of treated patients and regular monitoring of liver function tests is required in the early months of treatment”
> “The evidence for the efficacy of mirtazapine in patients with anxiety disorders is limited and inconsistent”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.9-3"></a>

### Network meta-analysis: mirtazapine and agomelatine

> “Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.9-4"></a>

### Imipramine and trazodone compared with diazepam

> “In this study response rates were 73% for imipramine-treated patients, compared to 69% for patients receiving trazodone and 66% for those receiving diazepam, and 47% for the placebo group.”
> “While the use of TCAs has largely been supplanted by the use of SSRIs for the treatment of GAD, they still represent a viable option for patients who fail to respond after multiple trials of SSRIs, SNRIs, and adjunctive psychopharmacologic interventions.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
